SCHEMBL3608348

SCHEMBL3608348

Nc1ccn(C2OC(CO)C(OP(=O)(O)O)C2O)c(=O)n1

nearest known ligand 0.84

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.69
THRB P10828 1/20 0.69
MTOR P42345 1/20 0.69
MDM2 Q00987 1/20 0.69
NCOA1 Q15788 1/20 0.69
NCOA3 Q9Y6Q9 1/20 0.69
P2RY2 P41231 1/20 0.52
PDE4D Q08499 1/20 0.51
PDE3A Q14432 1/20 0.51
SLC29A1 Q99808 1/20 0.51
CYP2C19 P33261 1/20 0.51
HIF1A Q16665 1/20 0.51
TSHR P16473 1/20 0.50
NT5E P21589 1/20 0.50
GLA P06280 1/20 0.50
ADORA1 P30542 1/20 0.48
ST6GAL1 P15907 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11617377 1.00 LMNA (0.69) LMNATHRBMTORMDM2NCOA1
SCHEMBL10177274 1.00 LMNA (0.69) LMNATHRBMTORMDM2NCOA1
SCHEMBL79966 1.00 LMNA (0.69) LMNATHRBMTORMDM2NCOA1
SCHEMBL2212574 1.00 LMNA (0.69) LMNATHRBMTORMDM2NCOA1
SCHEMBL18151989 1.00 LMNA (0.69) LMNATHRBMTORMDM2NCOA1
SCHEMBL4735554 1.00 LMNA (0.69) LMNATHRBMTORMDM2NCOA1
SCHEMBL28151155 0.96 LMNA (0.67) LMNATHRBMTORMDM2NCOA1
SCHEMBL2537576 0.92 LMNA (0.64) LMNATHRBMTORMDM2NCOA1
SCHEMBL11327207 0.92 LMNA (0.64) LMNATHRBMTORMDM2NCOA1
SCHEMBL39903 0.92 P2RY2 (0.58) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240426830-A1 CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS THE TRUSTEES OF INDIANA UNIVERSITY 2024-12-26 US claimed
WO-2023069598-A1 CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2023-04-27 WO claimed
CN-113624862-B Metabolome covering multiple metabolites, metabolic flux analysis method and kit 清华大学 2023-04-07 CN claimed
US-6727076-B2 UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES BIOLOG, INC. 2004-04-27 US claimed
US-6472201-B1 GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES BIOLOG, INC. 2002-10-29 US claimed
EP-4735595-A1 OLIGONUCLEOTIDES FOR TREATING NEUROMUSCULAR DISEASES Hospital Sant Joan de Deu (ES) 2026-05-06 EP disclosed
US-20260022367-A1 BROAD SPECTRUM NANOZYMES UNIV FLORIDA (US) 2026-01-22 US disclosed
WO-2025262108-A1 MULTIFUNCTIONALIZED NANOPARTICLES FOR THE DELIVERY OF OLIGONUCLEOTIDES AND USES THEREOF INSTITUT QUIMIC DE SARRIA CETS FUNDACIO PRIVADA (ES) 2025-12-26 WO disclosed
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE TEAM MEDICAL, LLC 2025-09-18 US disclosed
WO-2025003222-A1 OLIGONUCLEOTIDES FOR TREATING NEUROMUSCULAR DISEASES HOSPITAL SANT JOAN DE DEU (ES) 2025-01-02 WO disclosed
US-20240426830-A1 CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS THE TRUSTEES OF INDIANA UNIVERSITY 2024-12-26 US disclosed
WO-2024235848-A1 NOVEL T CELL RECEPTORS FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2024-11-21 WO disclosed
WO-2004008105-A2 DETECTION OF LIGAND/ANTILIGAND COMPLEX FORMATION BY ELECTROMAGNETICALLY DETECTABLE BULK PROPERTY MEASUREMENT MDS, INC., DOING BUSINESS AS MDS SCIEX (CA) 2004-01-22 WO disclosed
US-20040014045-A1 Detection of ligand/antiligand complex formation by electromagnetically detectable bulk property measurement SIGNATURE BIOSCIENCE INC. A CORPORATION OF CALIFORNIA (US) 2004-01-22 US disclosed
US-20030162164-A1 Comparative phenotype analysis of cells, including testing of biologically active compounds BIOLOG, INC. 2003-08-28 US disclosed
US-20030148413-A1 Comparative phenotype analysis BIOLOG, INC. (CA) 2003-08-07 US disclosed
US-6472201-B1 GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES BIOLOG, INC. 2002-10-29 US disclosed
US-20020110848-A1 Comparative phenotype analysis BIOLOG, INC. 2002-08-15 US disclosed
US-6387651-B1 PREPARING SUSPENSIONS OF EACH CELL PREPARATION, PLACING SUSPENSIONS INTO TESTING DEVICE, DETECTING RESPONSE OF CELL PREPARATIONS TO AT LEAST ONE TEST SUBSTRATE, AND COMPARING RESPONSES BIOLOG, INC. 2002-05-14 US disclosed
JP-2000300206-A AGENT FOR IMPARTING BODILY TASTE NIPPON PAPER INDUSTRIES CO LTD 2000-10-31 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE SYNCRIP, SNRPA, RNASE1 LMNA 240/4885THRB 4546/4885MTOR 3099/4885
US-20260022367-A1 BROAD SPECTRUM NANOZYMES NSUN3, RNGTT, NSUN2 LMNA 2844/4885THRB 2132/4885MTOR 3910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.